Methods: Data on hospitalizations for STEMI from 2000 through 2010 were extracted from hospital discharge record databases from all hospitals in Lombardia (a Northern Italy region with high density population). Main outcome measures were inhospital mortality and treatment modality by sex. Treatment modalities included medical therapy alone or an invasive approach, the latter consisting of coronary angiography alone, percutaneous coronary intervention (PCI), or coronary artery bypass graft surgery. Multivariable logistic regression was performed to assess the impact of female sex and of treatment modality on mortality after adjusting for age, and comorbidities. Results: A total of 92807 patients with STEMI, 66.4% men and 33.6% women were enrolled. Women were older than men (mean 75.1 yrs vs 64.1 yrs, p<0.0001) and had a higher prevalence of chronic renal failure (p<0.001). In-hospital mortality presented a small decrease from 7.5% in 2000 to 6.3% in 2010 among men, while it remained higher and substantially constant over time among women (16.4% in 2000, 16.2% in 2010). The use of an invasive approach increased over time in both sexes (from 55% in 2000 to 91% in 2010 in men and from 36% in 2000 to 70% in 2010 in women). The use of PCI increased from 32% in 2000 to 82% in 2010 in men; and from 21% in 2000 to 57% in 2010 in women. At multivariable regression, an invasive approach (odds ratio (OR) 0.23, 95% confidence interval (CI), 0.21-0.25, p<0.001) was associated with a significant reduction in mortality, while female sex was not a predictor of mortality (OR 0.96, P¼0.18). Conclusions: In-hospital mortality remains higher in women than in men, although female sex is not a significant predictor of mortality. Despite temporal increases in the use of an invasive approach, women are more often treated conservatively.
Background: The risk for recurrent ischemic events following ST-segment elevation myocardial infarction (STEMI) gradually declines. However, current guidelines suggest consistent therapy from presentation out to 12 months. We sought to characterize the actuarial daily ischemic risk (ADIR) in the 12 months year after STEMI. Methods: Ischemic event rates for all 3602 patients enrolled in the prospective HORIZONS-AMI trial were categorized according to the timing of their occurrence in three groups: Group 1: during index hospitalization, Group 2: from hospital discharge to 30 days, and Group 3: from 30 days post hospital discharge to 1 year. Ischemic events included: All-cause death, cardiovascular (CV) death, non-CV death, reinfarction (MI), definite ST and the composite of CV death, MI or definite ST. The ADIR for each event was calculated based on the actual patient days of follow-up for each group. Results: Highly significant reductions in ADIR were observed as patients transitioned from Group 1 to Groups 2 and 3 respectively (Table) . The degree of ADIR reduction approached or exceeded a full order of magnitude for all events except for non-CV death. Accordingly, the relative risk for the composite of CV death, MI or definite p<0 .0001) for Group 1 vs. Group 2, 6.31 (4.62 -8.62, p<0.0001) for Group 2 vs. Group 3 and 95.94 (76.06 -121.02, p<0.0001) for Group 1 vs. Group 3. Conclusions: Conclusions: The risk for CV death and recurrent ischemic events following an index STEMI treated with primary PCI dramatically declines following hospital discharge out to the first 30 days and declines even further between day 30 and one year. These data suggest that a tailored approach to anti-ischemic protection, with more potent agents administered in the acute and sub-acute phases and less potent agents (with lower bleeding potential) administered after 30 days, warrants investigation. Background: We sought to analyze in ST-elevation myocardial infarction (STEMI) patients the impact of rheolytic thrombectomy (RT) in comparison to manual thrombus aspiration (MTA) on extension of microvascular obstruction (MVO) and infarct size (IS) as well as on 1-year left ventricular (LV) volumes and ejection fraction (EF) by cardiac magnetic resonance imaging (MRI). Methods: Eighty STEMI patients ( 6 hours from symptom onset) reperfused by primary angioplasty with routine abciximab therapy were randomly allocated (1:1) to a RT or MTA. MRI was performed within 10 AE 6 days in 37 patients (19 RT, 18 MTA), and after 1 year in 19 patients (9 RT). IS and MVO were measured 15 min after gadolinium injection with late enhancement sequences and were analyzed quantitatively (as percentage of the left ventricular mass -gr/LV mass-) at a core laboratory blinded to randomization. Results: Baseline clinical characteristics were similar between the RT and MTA groups, as well as baseline TIMI thrombus grade (4.47 AE 0.84 vs. 4.67 AE 0.76, p¼0.453). After thrombectomy, in RT compared with MTA group the thrombus grade decreased to 1.11 AE 1.04 vs. 2.17 AE 1.29 (P¼0.04), and after infarct artery stenting TIMI 3 flow was 100% vs. 89% (P¼0.204), and ST-elevation resolution greater than 70% at 60 minutes was 89% vs. 72% (P¼0.198), respectively. RT compared with MTA group did not reduced significantly myocardial .1) vs. 19.0% (7-28.5) , P¼0.224] as well as the extent of MVO [0.0% (0.0-0.17) vs. 0.6% (0.0-1.4), P¼0.117], but a trend towards a lower incidence of MVO was observed (16% vs. 44%, P¼0.056). At 1-year, the IS did not change .1) vs. MTA 11.4% (6.5-27.8), P¼0.253] and the recovery (baseline-1-year) of LV EF was not different in both groups (RT 1.9AE4.5% vs. MTA 1.1AE8.3%, P¼0.626), with a reduction of LV volumes found only in RT group (EDV: RT -9.3AE15 ml vs. MTA 9AE29.8 ml, P¼.115; ESV: RT -8.5AE15.2 ml vs. MTA 3.1AE20.3 ml, P¼.180, respectively). Conclusions: In setting of STEMI, at 1-year RT in comparison to MTA did not reduce significantly the IS. However a more favorable change of LV volumes were found, likely due to a more effective thrombus removal and a lower incidence of MVO by RT.
TCT-248
Immediate Stenting in Comparison with Surgical Revascularization Strategy in Patients with Non-ST Elevation Acute Coronary Syndrome and Multivessel Coronary Artery Disease -The MILESTONE Registry.
Piotr P. Buszman 1 , Andrzej Bochenek 1 , Marek Gierlotka 2 , Mariusz Gasior 2 , R. Stefan Kiesz 3 , Krzysztof P. Milewski 4 , Wojciech Wojakowski 5 , Marian Zembala 2 , Lech Polonski 2 , Buszman E. Pawel 6
